Litao Nie , Yimei Liao , Rui Zhou , Xiao Liang , Xiaowei Wan , Xin Li , Min Su
{"title":"calycosin靶向脱铁性肝癌的抗肝癌机制","authors":"Litao Nie , Yimei Liao , Rui Zhou , Xiao Liang , Xiaowei Wan , Xin Li , Min Su","doi":"10.1016/j.imed.2022.06.001","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>Ferroptosis, a pathologic state induced by lipid-driven oxidative stress, is associated with the development of human cancers. Calycosin, a natural compound with antioxidant and anti-inflammatory activities, has promising antitumor effects. However, the ferroptosis-related mechanism of calycosin in the treatment of hepatic carcinoma has not been reported.</p></div><div><h3>Methods</h3><p>This study applied network pharmacology and bioinformatic approaches (including Gene Ontology and Kyoto Encyclopedia of Genes and Genomes pathway enrichment analysis) to investigate the pharmacologic targets and mechanism of action of calycosin in the treatment of hepatic carcinoma through targeting ferroptosis. By searching online databases including The Cancer Genome Atlas, FerrDb, GeneCards, SwissTargetPrediction, SuperPred, BindingDB, TargetNet, BATMAN-TCM, and Drugbank, we identified 13 ferroptosis-related putative target genes of calycosin against hepatic carcinoma including <em>IL-6, PTGS2, SRC, HRAS, NQO1, NOX4, PGK1, G6PD, GPI, MIF, NOS2, ALDOA</em>, and <em>SQSTM1</em>.</p></div><div><h3>Results</h3><p>Molecular docking analysis revealed that calycosin potentially binded directly with the target proteins IL-6, PTGS2, and SRC. Functional enrichment analysis of these proteins indicated that they were involved in gluconeogenesis and apoptosis through regulation of ERK1, ERK2, and MAPK activities (<em>P</em> < 0.05).</p></div><div><h3>Conclusion</h3><p>Calycosin exerts antitumor effects in hepatic carcinoma by targeting ferroptosis through regulation of IL-6, PTGS2, and SRC.</p></div>","PeriodicalId":73400,"journal":{"name":"Intelligent medicine","volume":"3 3","pages":"Pages 173-179"},"PeriodicalIF":4.4000,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Anti-hepatic carcinoma mechanisms of calycosin through targeting ferroptosis\",\"authors\":\"Litao Nie , Yimei Liao , Rui Zhou , Xiao Liang , Xiaowei Wan , Xin Li , Min Su\",\"doi\":\"10.1016/j.imed.2022.06.001\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><p>Ferroptosis, a pathologic state induced by lipid-driven oxidative stress, is associated with the development of human cancers. Calycosin, a natural compound with antioxidant and anti-inflammatory activities, has promising antitumor effects. However, the ferroptosis-related mechanism of calycosin in the treatment of hepatic carcinoma has not been reported.</p></div><div><h3>Methods</h3><p>This study applied network pharmacology and bioinformatic approaches (including Gene Ontology and Kyoto Encyclopedia of Genes and Genomes pathway enrichment analysis) to investigate the pharmacologic targets and mechanism of action of calycosin in the treatment of hepatic carcinoma through targeting ferroptosis. By searching online databases including The Cancer Genome Atlas, FerrDb, GeneCards, SwissTargetPrediction, SuperPred, BindingDB, TargetNet, BATMAN-TCM, and Drugbank, we identified 13 ferroptosis-related putative target genes of calycosin against hepatic carcinoma including <em>IL-6, PTGS2, SRC, HRAS, NQO1, NOX4, PGK1, G6PD, GPI, MIF, NOS2, ALDOA</em>, and <em>SQSTM1</em>.</p></div><div><h3>Results</h3><p>Molecular docking analysis revealed that calycosin potentially binded directly with the target proteins IL-6, PTGS2, and SRC. Functional enrichment analysis of these proteins indicated that they were involved in gluconeogenesis and apoptosis through regulation of ERK1, ERK2, and MAPK activities (<em>P</em> < 0.05).</p></div><div><h3>Conclusion</h3><p>Calycosin exerts antitumor effects in hepatic carcinoma by targeting ferroptosis through regulation of IL-6, PTGS2, and SRC.</p></div>\",\"PeriodicalId\":73400,\"journal\":{\"name\":\"Intelligent medicine\",\"volume\":\"3 3\",\"pages\":\"Pages 173-179\"},\"PeriodicalIF\":4.4000,\"publicationDate\":\"2023-08-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Intelligent medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2667102622000481\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"COMPUTER SCIENCE, INTERDISCIPLINARY APPLICATIONS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Intelligent medicine","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2667102622000481","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"COMPUTER SCIENCE, INTERDISCIPLINARY APPLICATIONS","Score":null,"Total":0}
引用次数: 0
摘要
背景脱铁症是一种由脂质驱动的氧化应激引起的病理状态,与人类癌症的发展有关。Calycosin是一种具有抗氧化和抗炎活性的天然化合物,具有良好的抗肿瘤作用。然而,calycosin治疗肝癌的脱铁相关机制尚未报道。方法应用网络药理学和生物信息学方法(包括Gene Ontology和Kyoto Encyclopedia of Genes and Genomes pathway富集分析),通过靶向脱铁性贫血,研究甲壳类毒素治疗肝癌的药理学靶点和作用机制。通过检索包括癌症基因组图谱、FerrDb、GeneCards、SwissTargetPrediction、SuperPred、BindingDB、TargetNet、BATMAN-TCM和Drugbank在内的在线数据库,我们鉴定了13个与脱铁性相关的calycosin抗肝癌的推定靶基因,包括IL-6、PTGS2、SRC、HRAS、NQO1、NOX4、PGK1、G6PD、GPI、MIF、NOS2、ALDOA、,和SQSTM1。结果分子对接分析显示,calycosin可能与靶蛋白IL-6、PTGS2和SRC直接结合。这些蛋白的功能富集分析表明,它们通过调节ERK1、ERK2和MAPK活性参与糖异生和细胞凋亡(P<;0.05)。
Anti-hepatic carcinoma mechanisms of calycosin through targeting ferroptosis
Background
Ferroptosis, a pathologic state induced by lipid-driven oxidative stress, is associated with the development of human cancers. Calycosin, a natural compound with antioxidant and anti-inflammatory activities, has promising antitumor effects. However, the ferroptosis-related mechanism of calycosin in the treatment of hepatic carcinoma has not been reported.
Methods
This study applied network pharmacology and bioinformatic approaches (including Gene Ontology and Kyoto Encyclopedia of Genes and Genomes pathway enrichment analysis) to investigate the pharmacologic targets and mechanism of action of calycosin in the treatment of hepatic carcinoma through targeting ferroptosis. By searching online databases including The Cancer Genome Atlas, FerrDb, GeneCards, SwissTargetPrediction, SuperPred, BindingDB, TargetNet, BATMAN-TCM, and Drugbank, we identified 13 ferroptosis-related putative target genes of calycosin against hepatic carcinoma including IL-6, PTGS2, SRC, HRAS, NQO1, NOX4, PGK1, G6PD, GPI, MIF, NOS2, ALDOA, and SQSTM1.
Results
Molecular docking analysis revealed that calycosin potentially binded directly with the target proteins IL-6, PTGS2, and SRC. Functional enrichment analysis of these proteins indicated that they were involved in gluconeogenesis and apoptosis through regulation of ERK1, ERK2, and MAPK activities (P < 0.05).
Conclusion
Calycosin exerts antitumor effects in hepatic carcinoma by targeting ferroptosis through regulation of IL-6, PTGS2, and SRC.